TGN treatment also decreases the secretion of TGFβ3, IL-6, and VEGF by CAF-containing tumor-like constructs, all of which facilitate tumor-associated angiogenesis, drug resistance, and metastasis [153]. The gene discussed is VEGFA; the disease is neoplasm.